-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $13

Benzinga·05/28/2025 13:24:05
Listen to the news
Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $16 to $13.